Rating on ILMN2 Oct 2023 10:35
As for next-generation genomic sequencing, Bernstein said it’s bullish on Pacific Biosciences (NASDAQ:PACB) but bearish on sub-sector giant Illumina (NASDAQ:ILMN), due in part to a shift from short-read sequencing by synthesis, or SBS, which Illumina dominates, to a “more competitive landscape” that includes technologies such as long-read sequencing.
In the case of Illumina, Bernstein asserted that its “monopoly” was under attack, making it the relative “loser” in the space. Bernstein rated Illumina at underperform, despite a “huge collapse” of its share price. “We think there is further downside,” Bernstein added, setting Illumina’s price target at $111.
Meanwhile, Bernstein said it viewed PacBio as the relative “winner,” stating that PacBio’s pipeline was set up to grab market share in both the long and short-read categories. “PacBio is at a huge point of inflection in growth,” the investment firm added. Bernstein rated PacBio outperform, with a price target of $11.